
    
      The study is a prospective randomised open, blinded endpoint trial with balanced
      randomisation (1:1) conducted in seven outpatient clinics in Denmark. Follow-up visits for
      patients in the intervention group are scheduled to occur at baseline and then after 2, 4 and
      12 weeks and thereafter every third month for 5 years after randomisation. The control group
      will be monitored for RA disease activity and comorbidity after 2, 4 weeks, 12 weeks and
      thereafter following national guidelines for RA. Prevention of CVD risk factors in the
      control group will be treated in general practice according to national guidelines for
      diabetes (2011), hypertension (2009) and CVD (2013).
    
  